Cellectar biosciences provides strategic update on clinical development, pipeline programs and corporate restructuring

Evaluating strategic options for iopofosine i 131 a late-stage clinical program with compelling phase 2 data and a substantial market opportunity

CLRB Ratings Summary

CLRB Quant Ranking